Personalis Announces Participation in the European Society of Human Genetics Conference

Services for researchers engaging in case-control, family-based, or proband-only genome studies of disease and pharmacogenomics

Menlo Park, CA – Personalis, Inc. today announced that it will be exhibiting at the European Society of Human Genetics Conference in Paris, France beginning Sunday, June 9, 2013.  Personalis will launch its Genome Services for Research and Clinical samples, focusing on accuracy in sequencing, analysis, and interpretation of human genomes to the European market.

Personalis’ Genome Services include our Accuracy and Content Enhanced (ACE™) Exome technology.  Using additional custom targeted capture, we aim to finish genes in the medical exome and add medically interpretable content outside the exons.  This has been shown to benefit work in medical genetics, pediatrics, cardiology, neurology, psychiatry, pharmacogenomics, and other areas of medicine.

Clinical quality genome interpretation also requires accurate and comprehensive databases of genetic variation. Personalis has the largest and most comprehensive manually-curated database in the world linking genetic variation with disease.  We have also signed an exclusive license for commercialization of PharmGKB®, the premier database linking genetic variation with drug metabolism and adverse events. Personalis also annotates genomes with information from over 30 databases. When combined with Personalis ACE (Accuracy and Content Enhanced) Technology™ for exome sequencing and powerful variant calling algorithms, researchers and clinicians are able to rapidly obtain the most comprehensive sequence analysis available. Personalis CEO, John West, stated “We are pleased to extend this offering to the European community and are committed to expanding our global footprint to enable researchers and clinicians worldwide to take advantage of our products.”

About Personalis, Inc.

Personalis, Inc. ( is a leading precision medicine company focused on advanced NGS-based clinical diagnostic, clinical trial and research services for cancer and inherited genetic disease.  Personalis also provides DNA sequencing and data analysis of human genomes.

The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited.

Media Contact for Personalis:

Jennifer Havlek